Deutsche Bank analysts expect to see substantial growth opportunities in China’s monoclonal antibodies (mAbs) market in the coming five years, naming 3SBio and Shanghai Fosun Pharmaceutical as among the first-movers in the sector. Monoclonal antibodies …
( read original story …)
